Tecartus

DRUG2 trials

Sponsors

Masonic Cancer Center, University of Minnesota, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaLarge B-cell Lymphoma

Phase 2

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruitingNCT03642626

Masonic Cancer Center, University of MinnesotaAcute Lymphoblastic Leukemia, Large B-cell Lymphoma

Start: 2018-12-18End: 2028-06-01Updated: 2026-01-23

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingNCT06144606

H. Lee Moffitt Cancer Center and Research InstituteAcute Lymphoblastic Leukemia, B-Cell Lymphoblastic Leukemia

Start: 2023-12-26End: 2028-11-15Target: 60Updated: 2026-03-31

Related Papers

Phase 2 study of brexu-cel in minimal residual disease positive B-cell acute lymphoblastic leukemia

Blood2025-11-03